Does low LH with testosterone therapy cause weekly peaks and troughs that change symptoms and side effects?

In the context of testosterone replacement therapy (TRT), the combination of low luteinizing hormone (LH) and exogenous testosterone administration fundamentally alters the body’s androgen landscape. The resulting pharmacokinetic profile is characterized by distinct peaks and troughs that differ significantly from natural hormonal rhythms.

Clinical and effectiveness evidence

The use of injectable testosterone esters, such as testosterone cypionate or enanthate, creates a predictable "roller coaster" effect in serum concentrations.

• Dosing impact: Standard weekly injections of 100-200 mg often lead to supraphysiological peaks within 24 to 72 hours, followed by a gradual decline to sub-therapeutic levels (troughs) toward the end of the dosing interval.
• Symptom recurrence: Patients frequently report a recurrence of hypogonadal symptoms—such as fatigue, irritability, and low libido—during these trough periods.
• Stability through frequency: Increasing dosing frequency (e.g., twice-weekly or every other day) has been shown to reduce the peak-to-trough ratio, leading to more stable mood and energy levels compared to weekly or bi-weekly regimens.

Side effect profile

The variability in androgen exposure is a primary driver of common TRT-related side effects, particularly those sensitive to high peak concentrations.

• Erythrocytosis: High testosterone peaks aggressively stimulate erythropoiesis. Research indicates that injectable testosterone is associated with higher rates of elevated hematocrit compared to steady-state delivery methods like gels or nasal sprays.
• Aromatization: Supraphysiological peaks can lead to increased conversion of testosterone to estradiol (aromatization). This may exacerbate side effects such as gynecomastia, water retention, and mood instability.
• Dermatological effects: Rapid surges in androgens can stimulate sebaceous glands, increasing the risk of acne and oily skin.

Mechanistic explanations

The variability described is a direct consequence of the suppression of the hypothalamic-pituitary-gonadal (HPG) axis.

• LH suppression: Exogenous testosterone provides negative feedback to the pituitary gland, suppressing LH secretion. In a healthy state, LH drives the pulsatile, endogenous production of testosterone by the Leydig cells, which provides a natural "buffer" or steady baseline.
• Loss of endogenous buffer: When LH is suppressed, this natural production ceases. Consequently, serum testosterone levels become entirely dependent on the absorption and clearance rates of the injected ester. Without the endogenous buffer, the patient is fully exposed to the exponential decay of the exogenous drug, creating the weekly peaks and troughs.

Bottom line

Low LH levels during testosterone therapy signify the loss of natural hormonal regulation, making the patient susceptible to significant androgen fluctuations. These peaks and troughs are clinically linked to inconsistent symptom relief and an increased risk of side effects like elevated hematocrit and mood swings, which can often be mitigated by increasing injection frequency.